NCT06269133View on ClinicalTrials.gov

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients

Active, not recruitingOBSERVATIONAL
Enrollment

1,000

Participants

Timeline

Start Date

February 21, 2024

Primary Completion Date

March 31, 2027

Study Completion Date

June 23, 2027

Conditions
Advanced Non-small Cell Lung Cancer
Interventions
DRUG

REGN2810

No study specific interventions for this non-interventional-observational study; patients had previously been administered this treatment.

OTHER

Platinum-doublet chemotherapy

No study specific interventions for this non-interventional-observational study; patients had previously been administered this treatment.

Trial Locations (1)

10591

Regeneron Research Facility, Tarrytown

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY

NCT06269133 - Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients | Biotech Hunter | Biotech Hunter